Half-year report · HY
9989.TEDINET S100X3XF
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥418.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥801.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥395.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥23.1bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥21.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥22.9bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥43.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.8bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥22.7bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥20.5bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥30.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥15.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥14.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥450.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥444.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥420.0bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥173.2bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥174.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥277.5bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥269.7bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥260.8bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥66.1bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥65.0bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥66.1bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥65.0bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥63.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥69.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥21.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥41.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥19.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥17.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥35.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥18.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥10.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥130.54 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥262.91 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥122.02 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 61.6% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥30.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥30.4bn |
| Discount Storereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥181.8bn |
| Discount Storereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥181.8bn |
| Discount Storereportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6m |
| Discount Storereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥9.8bn |
| Drug Storereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥267.0bn |
| Drug Storereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥236.6bn |
| Drug Storereportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥30.4bn |
| Drug Storereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥13.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥448.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥418.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥30.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥23.1bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥28.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥28.5bn |
| Discount Storereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥168.4bn |
| Discount Storereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥168.4bn |
| Discount Storereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6m |
| Discount Storereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥8.6bn |
| Drug Storereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥255.6bn |
| Drug Storereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥227.2bn |
| Drug Storereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥28.5bn |
| Drug Storereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥424.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥395.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥28.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥21.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Retirement benefit expenses sga | Prior1InterimDuration | 359000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 361000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E03226-000DrugStoreReportableSegmentsMember | 227169000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E03226-000DiscountStoreReportableSegmentsMember | 168416000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 395585000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 395585000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E03226-000DrugStoreReportableSegmentsMember | 28454000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E03226-000DiscountStoreReportableSegmentsMember | 6000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 28460000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -28460000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E03226-000DrugStoreReportableSegmentsMember | 255623000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E03226-000DiscountStoreReportableSegmentsMember | 168423000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 424046000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -28460000000 | JPY |
| Net sales | Prior1InterimDuration | 395585000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E03226-000DrugStoreReportableSegmentsMember | 12643000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E03226-000DiscountStoreReportableSegmentsMember | 8568000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 21212000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1InterimDuration | 21212000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E03226-000DrugStoreReportableSegmentsMember | 236622000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E03226-000DiscountStoreReportableSegmentsMember | 181815000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 418437000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 418437000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E03226-000DrugStoreReportableSegmentsMember | 30406000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E03226-000DiscountStoreReportableSegmentsMember | 6000000 | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 30413000000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -30413000000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E03226-000DrugStoreReportableSegmentsMember | 267028000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E03226-000DiscountStoreReportableSegmentsMember | 181822000000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 448850000000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -30413000000 | JPY |
| Net sales | InterimDuration | 418437000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E03226-000DrugStoreReportableSegmentsMember | 13283000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E03226-000DiscountStoreReportableSegmentsMember | 9774000000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 23057000000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | InterimDuration | 23057000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-14 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第63期中(自 2025年４月１日 至 2025年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社サンドラッグ | |
| Company name in english cover page | FilingDateInstant | SUNDRUG CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 CEO 貞方 宏司 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |